Literature DB >> 21721042

Uncertainties in the prevention and treatment of glucocorticoid-induced osteoporosis.

Karen E Hansen1, H Alexander Wilson, Carol Zapalowski, Howard A Fink, Salvatore Minisola, Robert A Adler.   

Abstract

Much knowledge has accrued since the 2001 American College of Rheumatology (ACR) guidelines were published to assist clinicians in the prevention and treatment of glucocorticoid-induced osteoporosis (GIO). Therefore, the ACR undertook a comprehensive effort to review the literature and update the GIO guidelines [Grossman JM, Gordon R, Ranganath VK, et al. American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res (Hoboken). 2010;62:1515-1526]. Herein, we review the new guidelines for JBMR readers, highlighting the changes introduced by the 2010 publication. We discuss several patient scenarios for which the new treatment guidelines do not apply, or for which our committee interprets existing literature differently and suggests an alternative approach.
Copyright © 2011 American Society for Bone and Mineral Research.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21721042     DOI: 10.1002/jbmr.362

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  17 in total

Review 1.  Glucocorticoid-induced osteoporosis and osteonecrosis.

Authors:  Robert S Weinstein
Journal:  Endocrinol Metab Clin North Am       Date:  2012-05-23       Impact factor: 4.741

2.  Prevention of glucocorticoid induced bone changes with beta-ecdysone.

Authors:  Weiwei Dai; Li Jiang; Yu-An Evan Lay; Haiyan Chen; Guoqin Jin; Hongliang Zhang; Alexander Kot; Robert O Ritchie; Nancy E Lane; Wei Yao
Journal:  Bone       Date:  2015-01-10       Impact factor: 4.398

Review 3.  New anabolic therapies for osteoporosis.

Authors:  Salvatore Minisola; Cristiana Cipriani; Marco Occhiuto; Jessica Pepe
Journal:  Intern Emerg Med       Date:  2017-08-05       Impact factor: 3.397

4.  Approach in glucocorticoid-induced osteoporosis prevention: results from the Italian multicenter observational EGEO study.

Authors:  U Massafra; S Migliaccio; C Bancheri; F Chiacchiararelli; F Fantini; F Leoni; L S Martin; A Migliore; B Muccifora; C Napolitano; R Pastore; A Ragno; S Ronzoni; M Rotondi; M Tibaldi; P Villa; V Vinicola; E D'Erasmo; P Falaschi; G Minisola
Journal:  J Endocrinol Invest       Date:  2012-03-06       Impact factor: 4.256

5.  Treatment of skeletal impairment in patients with endogenous hypercortisolism: when and how?

Authors:  A Scillitani; G Mazziotti; C Di Somma; S Moretti; A Stigliano; R Pivonello; A Giustina; A Colao
Journal:  Osteoporos Int       Date:  2013-12-06       Impact factor: 4.507

6.  Glucocorticoid-induced osteoporosis: pathophysiological role of GH/IGF-I and PTH/VITAMIN D axes, treatment options and guidelines.

Authors:  Gherardo Mazziotti; Anna Maria Formenti; Robert A Adler; John P Bilezikian; Ashley Grossman; Emilia Sbardella; Salvatore Minisola; Andrea Giustina
Journal:  Endocrine       Date:  2016-10-20       Impact factor: 3.633

7.  Oral alendronate can suppress bone turnover but not fracture in kidney transplantation recipients with hyperparathyroidism and chronic kidney disease.

Authors:  Sakura Yamamoto; Atsushi Suzuki; Hitomi Sasaki; Sahoko Sekiguchi-Ueda; Shogo Asano; Megumi Shibata; Nobuki Hayakawa; Shuji Hashimoto; Kiyotaka Hoshinaga; Mitsuyasu Itoh
Journal:  J Bone Miner Metab       Date:  2012-10-18       Impact factor: 2.626

Review 8.  A review of lifestyle, smoking and other modifiable risk factors for osteoporotic fractures.

Authors:  Bo Abrahamsen; Dorthe Brask-Lindemann; Katrine Hass Rubin; Peter Schwarz
Journal:  Bonekey Rep       Date:  2014-09-03

9.  Clinical role of bisphosphonate therapy.

Authors:  Geeta Hampson; Ignac Fogelman
Journal:  Int J Womens Health       Date:  2012-09-03

Review 10.  Cortical remodeling during menopause, rheumatoid arthritis, glucocorticoid and bisphosphonate therapy.

Authors:  Daniel Aeberli; Georg Schett
Journal:  Arthritis Res Ther       Date:  2013-03-21       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.